UNSPSC 51141555: Dulozafone

This classification denotes an anticonvulsant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier BK2633656Q. European Medicines Agency schedules Dulozafone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06425MIG. Dulozafone generally arises in the molecular formula C20H22CL2N2O4. The term DULOZAFONE is an International Non-Proprietary Name or INN. DULOZAFONE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule dulozafone under HS 29242995 and SITC 51479. As of Q4 2014, DULOZAFONE remains the US FDA Preferred Term for this commodity. Dulozafone bears US NLM identifiers UMLS ID C0642769 and NCI Concept Code C65497. SMILES: CLC1CC(C(N(C(=O)CN(CCO)CCO)C)CC1)C(=O)C1C(CL)CCCC1.

UNSPSC 51141555 Dulozafone is a Commodity code that captures pharmaceutical products procured by state and local health and human services agencies. Recent state and local opportunities under this code show government purchases of naloxone, generic multi-source pharmaceuticals, over-the-counter products, and specialty pharmacy services supporting public health missions and employee benefit programs. State and local issuing bodies soliciting under the code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted recent opportunities; the Texas Health and Human Services Commission issued an exploratory Request for Information to evaluate direct-to-manufacturer prescription models. Vendors responding to these solicitations must meet FDA compliance, current Good Manufacturing Practices certification, Drug Supply Chain Security Act compliance, specific insurance requirements (commercial general liability typically $5,000,000 per occurrence or greater), and E-Verify employment eligibility verification. Contracts typically run two to three years with renewal options, and pricing is often evaluated as a primary factor alongside administrative compliance and product availability.

Recent activity concentrates in Florida, Minnesota, Texas, and other participating states in the MMCAP cooperative purchasing network. Seminole County's IFB60459723LAS, posted June 30, 2026 with response due July 26, 2023, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with vendors responsible for shipping costs and subject to a three-month probationary termination clause. MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, establishes multiple-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission's RFI HHS0017013, posted April 3, 2026, represents preliminary market research into direct-to-manufacturer pharmacy initiatives rather than a binding procurement, designed to inform future formal solicitation strategy.